EXPO vs. G, AMEH, FCN, DNB, CBZ, ICFI, HURN, VSEC, CRAI, and ACTG
Should you be buying Exponent stock or one of its competitors? The main competitors of Exponent include Genpact (G), Apollo Medical (AMEH), FTI Consulting (FCN), Dun & Bradstreet (DNB), CBIZ (CBZ), ICF International (ICFI), Huron Consulting Group (HURN), VSE (VSEC), CRA International (CRAI), and Acacia Research (ACTG).
Genpact (NYSE:G) and Exponent (NASDAQ:EXPO) are both mid-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.
Genpact has higher revenue and earnings than Exponent. Genpact is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.
Genpact has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Exponent has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
96.0% of Genpact shares are owned by institutional investors. Comparatively, 92.4% of Exponent shares are owned by institutional investors. 2.8% of Genpact shares are owned by company insiders. Comparatively, 2.1% of Exponent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Genpact currently has a consensus price target of $38.00, suggesting a potential upside of 13.96%. Exponent has a consensus price target of $100.00, suggesting a potential upside of 6.97%. Given Exponent's higher probable upside, research analysts clearly believe Genpact is more favorable than Exponent.
In the previous week, Genpact had 6 more articles in the media than Exponent. MarketBeat recorded 14 mentions for Genpact and 8 mentions for Exponent. Genpact's average media sentiment score of 1.19 beat Exponent's score of 0.69 indicating that Exponent is being referred to more favorably in the news media.
Genpact pays an annual dividend of $0.61 per share and has a dividend yield of 1.8%. Exponent pays an annual dividend of $1.12 per share and has a dividend yield of 1.2%. Genpact pays out 17.4% of its earnings in the form of a dividend. Exponent pays out 56.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Genpact has increased its dividend for 5 consecutive years and Exponent has increased its dividend for 11 consecutive years. Genpact is clearly the better dividend stock, given its higher yield and lower payout ratio.
Exponent has a net margin of 18.72% compared to Exponent's net margin of 14.21%. Genpact's return on equity of 28.13% beat Exponent's return on equity.
Genpact received 183 more outperform votes than Exponent when rated by MarketBeat users. Likewise, 68.30% of users gave Genpact an outperform vote while only 63.09% of users gave Exponent an outperform vote.
Summary
Genpact beats Exponent on 12 of the 20 factors compared between the two stocks.
Get Exponent News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exponent Competitors List
Related Companies and Tools
